Bullfrog AI (NASDAQ:BFRG – Get Free Report) and Bio-Techne (NASDAQ:TECH – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.
Valuation & Earnings
This table compares Bullfrog AI and Bio-Techne”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bullfrog AI | $120,000.00 | 85.75 | -$6.50 million | ($0.54) | -1.03 |
| Bio-Techne | $1.22 billion | 9.25 | $73.40 million | $0.69 | 104.48 |
Volatility and Risk
Bullfrog AI has a beta of -2.8, indicating that its stock price is 380% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and price targets for Bullfrog AI and Bio-Techne, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bullfrog AI | 1 | 1 | 0 | 0 | 1.50 |
| Bio-Techne | 1 | 13 | 3 | 0 | 2.12 |
Bio-Techne has a consensus price target of $68.08, indicating a potential downside of 5.57%. Given Bio-Techne’s stronger consensus rating and higher possible upside, analysts plainly believe Bio-Techne is more favorable than Bullfrog AI.
Insider and Institutional Ownership
1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 14.7% of Bullfrog AI shares are held by company insiders. Comparatively, 1.3% of Bio-Techne shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Bullfrog AI and Bio-Techne’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bullfrog AI | N/A | -217.80% | -174.57% |
| Bio-Techne | 9.05% | 13.57% | 10.66% |
Summary
Bio-Techne beats Bullfrog AI on 12 of the 14 factors compared between the two stocks.
About Bullfrog AI
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
About Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Bullfrog AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bullfrog AI and related companies with MarketBeat.com's FREE daily email newsletter.
